Study groups
|
n
|
Gln v Lys
|
Gln/Gln v Lys/Lys
|
Lys/Gln v Lys/Lys
|
Lys/Gln + Gln/Gln v Lys/Lys
|
Gln/Gln v Lys/Lys + Lys/Gln
|
---|
| |
OR (95% CI)
|
Ph
|
OR (95% CI)
|
Ph
|
OR (95% CI)
|
Ph
|
OR (95% CI)
|
Ph
|
OR (95% CI)
|
Ph
|
All
|
18
|
1.05(0.95–1.18)
|
<0.001
|
1.18(0.96–1.45)
|
0.030
|
1.02(0.90–1.17)
|
0.011
|
1.05(0.91–1.21)
|
0.001
|
1.11(0.98–1.26)
|
0.359
|
Ethnicity
|
18
| | | | | | | | | | |
Caucasian
|
11
|
1.08(0.96–1.23)
|
0.002
|
1.17(0.92–1.49)
|
0.008
|
1.06(0.91–1.25)
|
0.033
|
1.09(0.92–1.29)
|
0.004
|
1.11(0.97–1.27)
|
0.150
|
Asian
|
7
|
0.99(0.78–1.26)
|
0.026
|
1.13(0.75–1.70)
|
0.437
|
0.95(0.73–1.23)
|
0.062
|
0.97(0.74–1.27)
|
0.028
|
1.09(0.74–1.60)
|
0.687
|
Source
| | | | | | | | | | | |
HB
|
13
|
1.11(0.98–1.27)
|
0.001
|
1.26(0.98–1.61)
|
0.014
|
1.07(0.91–1.27)
|
0.009
|
1.11(0.93–1.33)
|
0.001
|
1.16(1.00–1.33)
|
0.273
|
Mix
|
1
|
1.05(0.88–1.26)
|
–
|
1.08(0.74–1.57)
|
–
|
1.08(0.83–1.41)
|
–
|
1.08(0.85–1.38)
|
–
|
1.04(0.73–1.47)
|
–
|
PB
|
3
|
0.86(0.62–1.19)
|
0.193
|
1.25(0.44–3.54)
|
0.870
|
0.82(0.57–1.18)
|
0.181
|
0.83(0.57–1.19)
|
0.168
|
1.26(0.45–3.57)
|
0.888
|
nest
|
1
|
0.78(0.56–1.08)
|
–
|
0.54(0.26–1.16)
|
–
|
0.90(0.56–1.46)
|
–
|
0.80(0.51–1.27)
|
–
|
0.58 (0.28–1.17)
|
–
|
Cancer type
|
6
|
0.95(0.72–1.25)
|
0.005
|
0.88(0.65–1.18)
|
0.185
|
0.87(0.60–1.27)
|
0.007
|
0.90(0.61–1.31)
|
0.002
|
0.97(0.73–1.28)
|
0.640
|
LC
|
2
|
0.72(0.48–1.10)
|
0.339
|
0.72(0.48–1.10)
|
0.383
|
0.66(0.48–0.91)
|
0.347
|
0.69(0.48–0.97)
|
0.285
|
0.93(0.64–1.34)
|
0.655
|
OC
|
3
|
1.16(0.68–1.98)
|
0.007
|
1.08(0.69–1.69)
|
0.075
|
1.18(0.67–2.05)
|
0.036
|
1.20(0.65–2.21)
|
0.012
|
1.02(0.66–1.58)
|
0.213
|
NPC
|
1
|
0.60(0.36–1.00)
|
–
|
0.97(0.06–15.66)
|
–
|
0.54(0.31–0.94)
|
–
|
0.55(0.32–0.95)
|
–
|
1.10(0.07–17.72)
|
–
|
- Ph P-value of Q-test for heterogeneity test, HB hospital-based study, PB population-based study, nest nested case–control study, LC laryngeal cancer, OC oral cancer, NPC nasopharyngeal cancer.